Sun Pharma Declares ₹11 Interim Dividend, Q3FY26 Net Profit Rises 16% to ₹33,688 Million
Sun Pharma reported Q3FY26 consolidated sales of ₹154,691 million (up 15.1% YoY) and a net profit of ₹33,688 million (up 16.0% YoY). The company declared an interim dividend of ₹11 per share. For nine months, sales were ₹436,604 million (up 11.3% YoY) and net profit was ₹87,654 million. India formulation sales grew 16.2% to ₹49,986 million.
The announcement includes key financial results (sales, profit, EBITDA) and a dividend declaration, which are material information for investors and significantly impact the company's stock valuation.
The company reported strong year-on-year growth in sales and net profit for both the quarter and nine-month periods, along with a declared interim dividend, indicating positive financial performance.
Sun Pharmaceutical Industries Limited announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved the unaudited standalone and consolidated financial results. An interim dividend of ₹11 per equity share for the financial year 2025-26 has been declared. The record date for this dividend is February 05, 2026, and payment will be made on or before February 16, 2026.
Consolidated financial highlights for Q3FY26 show sales of ₹154,691 million, a 15.1% year-on-year increase. Net profit for the quarter rose by 16.0% to ₹33,688 million. EBITDA stood at ₹49,485 million, up 23.4%, with an EBITDA margin of 31.9%. Profit before exceptional items and tax was ₹47,166 million, a 24.4% increase. R&D investment was ₹8,928 million, representing 5.8% of sales.
For the nine months ended December 31, 2025, consolidated sales were ₹436,604 million, an 11.3% growth. Net profit for this period was ₹87,654 million. EBITDA was ₹137,772 million, up 19.2%, with an EBITDA margin of 31.4%. R&D investment for the nine months was ₹25,783 million, or 5.9% of sales.
Kirti Ganorkar, Managing Director, highlighted well-rounded growth across businesses, particularly in India, Emerging Markets, and Global Innovative Medicines. New product launches include Unloxcyt in the US and Ilumya in India. Formulation sales in India for Q3FY26 were ₹49,986 million, a 16.2% growth, accounting for 32.3% of total consolidated sales.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.